What Are the Different Types of Ischemic Heart Disease? Complete 2026 Doctor’s Guide

by

What Are the Different Types of Ischemic Heart Disease? Complete 2026 Doctor’s Guide

By Dr. Sagar Rajkuwar, ENT Specialist, Nashik, Maharashtra, India
🌐 www.entspecialistinnashik.com

Short answer: The main types of ischemic heart disease (IHD) are: 1) stable angina, 2) silent myocardial ischaemia, 3) variant (Prinzmetal) angina caused by coronary vasospasm, 4) microvascular angina (INOCA/ANOCA), 5) unstable angina, 6) non-ST-elevation myocardial infarction (NSTEMI), 7) ST-elevation myocardial infarction (STEMI), 8) ischaemic cardiomyopathy & heart failure, 9) ischaemia-related arrhythmias & sudden cardiac death, and 10) MINOCA (myocardial infarction with non-obstructive coronary arteries). If you are asking what are the different types of ischemic heart disease, this 2026 ENT-authored guide, aligned with WHO, CDC, NHS, AHA/ACC 2023, and ESC 2024 Chronic Coronary Syndromes, walks you through each one in detail.

Table of Contents

  1. Introduction
  2. Why Classification Matters
  3. Type 1 β€” Stable Angina
  4. Type 2 β€” Silent Myocardial Ischaemia
  5. Type 3 β€” Variant (Prinzmetal / Vasospastic) Angina
  6. Type 4 β€” Microvascular Angina (INOCA / ANOCA)
  7. Type 5 β€” Unstable Angina
  8. Type 6 β€” Non-ST-Elevation MI (NSTEMI)
  9. Type 7 β€” ST-Elevation MI (STEMI)
  10. Type 8 β€” Ischaemic Cardiomyopathy & Heart Failure
  11. Type 9 β€” Arrhythmias & Sudden Cardiac Death
  12. Type 10 β€” MINOCA
  13. Classification by Mechanism (MI Types 1–5)
  14. Comparison Table
  15. Diagnosis Overview
  16. Treatment by Type
  17. Prevention β€” Common to All
  18. External Video Resource
  19. FAQs
  20. Conclusion
  21. References

1. Introduction

Ischemic heart disease is a spectrum, not a single disease. Each type carries different symptoms, prognosis and treatment. Understanding what are the different types of ischemic heart disease helps patients make sense of their diagnosis and partner better with their cardiologist.

2. Why Classification Matters

  • Targets precise treatment
  • Explains different investigations
  • Clarifies prognosis
  • Guides lifestyle advice
  • Helps coding, insurance, research

3. Type 1 β€” Stable Angina

3.1 Pathology

Fixed atherosclerotic plaque causing 50–70% narrowing. Supply fails only on increased demand.

3.2 Features

  • Predictable exertional chest pressure
  • Relieved by rest or sublingual nitrates in 2–5 minutes
  • Reproducible with the same workload
  • Canadian Cardiovascular Society (CCS) grade I–IV

3.3 Treatment

  • Lifestyle + statin + aspirin + anti-anginals (beta-blockers, CCB, long-acting nitrates, ranolazine, trimetazidine, ivabradine)
  • PCI or CABG if refractory or high-risk anatomy

4. Type 2 β€” Silent Myocardial Ischaemia

  • Objective evidence of ischaemia (ECG, imaging) without chest pain
  • Common in diabetics, elderly, after transplant
  • Detected on routine ECG, stress test, or ambulatory Holter
  • Carries the same mortality risk as symptomatic ischaemia

5. Type 3 β€” Variant (Prinzmetal / Vasospastic) Angina

  • Transient coronary vasospasm without fixed stenosis
  • Rest/early morning chest pain
  • ST-elevation during an episode that resolves with nitrates
  • Triggers: smoking, cold, cocaine, stress
  • Treatment: calcium-channel blockers (diltiazem, amlodipine) + long-acting nitrates; avoid non-selective beta-blockers and aspirin in high dose

6. Type 4 β€” Microvascular Angina (INOCA / ANOCA)

  • Angina with normal or near-normal coronaries on angiography
  • Due to dysfunction of coronary microvessels (<500 Β΅m)
  • Predominantly in women
  • Diagnosed with coronary flow reserve (CFR), index of microcirculatory resistance (IMR), acetylcholine testing
  • Treatment: ranolazine, nebivolol, nicorandil, ACE-I, high-intensity statin, L-arginine, enhanced external counterpulsation

7. Type 5 β€” Unstable Angina

  • New-onset, resting, or crescendo angina without troponin rise
  • Caused by plaque instability or partial thrombus
  • Represents an acute coronary syndrome β€” needs urgent cardiology
  • Treatment: dual antiplatelet, anticoagulation, high-intensity statin, risk-stratified invasive strategy

8. Type 6 β€” Non-ST-Elevation MI (NSTEMI)

  • Ischaemic symptoms + raised troponin + no persistent ST-elevation
  • Partial coronary occlusion or distal embolisation
  • Early invasive strategy within 24 h for high-risk
  • Treatment similar to UA but with longer-term dual antiplatelet therapy

9. Type 7 β€” ST-Elevation MI (STEMI)

  • Complete coronary occlusion β†’ full-thickness infarction
  • Persistent ST-elevation on ECG + raised troponin
  • Immediate reperfusion: primary PCI within 90 min, or fibrinolysis
  • Highest mortality β€” “time is muscle”

10. Type 8 β€” Ischaemic Cardiomyopathy & Heart Failure

  • Chronic reduction in ejection fraction after large or recurrent infarcts
  • HFrEF with LVEF <40%
  • Symptoms: breathlessness, orthopnoea, oedema, fatigue
  • Treatment “four pillars”: ACE-I/ARB/ARNI, beta-blocker, mineralocorticoid antagonist, SGLT2 inhibitor
  • Device therapy (ICD, CRT), revascularisation, LVAD, heart transplant

11. Type 9 β€” Arrhythmias & Sudden Cardiac Death

  • Ischaemia triggers ventricular tachycardia, ventricular fibrillation, atrial fibrillation
  • Responsible for 50% of IHD-related deaths
  • Secondary prevention: ICD if LVEF ≀35% despite optimal therapy
  • Public-access defibrillation and bystander CPR save lives

12. Type 10 β€” MINOCA

  • Myocardial infarction with non-obstructive coronary arteries
  • 5–10% of acute MI
  • Causes: plaque disruption without obstruction, coronary vasospasm, SCAD, microvascular dysfunction, Takotsubo, coronary embolism
  • Needs cardiac MRI and often intravascular imaging for exact aetiology
  • Treatment tailored to underlying mechanism

13. Classification by Mechanism (MI Types 1–5)

The Fourth Universal Definition of MI (2018, updated 2023) classifies MI by cause:

  • Type 1: plaque rupture + thrombus (classical)
  • Type 2: supply–demand mismatch (anaemia, sepsis, hypoxia, hypotension)
  • Type 3: cardiac death with suspected MI, before biomarker rise
  • Type 4a: MI associated with PCI
  • Type 4b: stent thrombosis
  • Type 4c: restenosis
  • Type 5: MI associated with CABG

This elegant scheme complements the clinical answer to what are the different types of ischemic heart disease.

14. Comparison Table

Type Mechanism Troponin ECG Urgency
Stable angina Fixed plaque Normal Normal or old changes Clinic
Silent ischaemia Fixed plaque, no pain Normal ST-depression on stress Clinic
Variant angina Vasospasm Normal Transient ST-elevation Clinic / ER during attack
Microvascular Small-vessel dysfunction Usually normal Variable Clinic
Unstable angina Plaque instability Normal Variable ST-T ER / cath lab
NSTEMI Partial occlusion Raised ST-depression / T inversion Early invasive
STEMI Total occlusion Raised Persistent ST-elevation Primary PCI <90 min
Ischaemic CMP Chronic damage Variable Q-waves, LBBB Clinic
Arrhythmic SCD Ischaemia-driven VT/VF Variable Arrhythmia Emergency / defibrillation
MINOCA Multiple non-obstructive Raised Variable ER + cardiac MRI

15. Diagnosis Overview

  • History and physical examination
  • ECG (resting, serial, stress)
  • Blood tests: troponin, lipids, HbA1c, Lp(a), hs-CRP, BNP
  • Echocardiography, cardiac MRI
  • CT coronary angiography, calcium score
  • Invasive angiography with FFR/iFR, acetylcholine testing
  • Holter monitoring, exercise testing

16. Treatment by Type

  • Common: Mediterranean diet, exercise, no tobacco, BP/LDL/glucose control, high-intensity statins, aspirin where indicated
  • Type-specific anti-anginals, calcium-channel blockers, nitrates, ranolazine
  • Reperfusion: primary PCI/CABG where indicated
  • Heart failure “four pillars”
  • ICD/CRT in selected cardiomyopathy patients
  • Cardiac rehabilitation for all post-ACS patients

17. Prevention β€” Common to All

  • Mediterranean/DASH diet
  • 150+ min/week aerobic activity + 2 strength sessions
  • No tobacco in any form
  • BP <130/80 mmHg
  • LDL at target with statins Β± ezetimibe Β± PCSK9 inhibitors
  • HbA1c <7% if diabetic; SGLT2 inhibitors / GLP-1 RAs
  • Weight & waist control (BMI <23 kg/mΒ² Asian cut-off)
  • Sleep 7–9 hours; treat OSA
  • Daily stress management
  • Vaccinations: annual flu, pneumococcal, COVID-19
  • Regular screening (lipids, glucose, CAC, Lp(a) once)

18. External Video Resource

Watch a 10-minute visual summary of what are the different types of ischemic heart disease:

YouTube: Types of Ischemic Heart Disease – AHA / BHF / Osmosis

19. FAQs

Q1. How many types of IHD are there?

Clinically, 10 overlapping types as listed above; by MI mechanism, 5 types per the Universal Definition.

Q2. Can one patient have more than one type?

Yes β€” stable angina today, STEMI tomorrow, ischaemic cardiomyopathy later. Progression is common.

Q3. What is INOCA?

Ischaemia with No Obstructive Coronary Arteries β€” includes microvascular and vasospastic angina.

Q4. Is Takotsubo an IHD?

Technically, it mimics IHD; it is a stress-induced cardiomyopathy, often with transient apical ballooning.

Q5. Which type is most common?

Stable angina / chronic coronary syndrome is the most common clinical presentation globally.

Q6. Which type is most lethal?

Anterior STEMI with cardiogenic shock has the highest short-term mortality.

Q7. Can microvascular angina be cured?

Not cured, but controlled well with ranolazine, nebivolol, nicorandil, statins, L-arginine, and lifestyle changes.

Q8. Does MINOCA need the same treatment as classical MI?

No β€” treatment is tailored to the underlying mechanism (vasospasm, SCAD, microvascular dysfunction, Takotsubo).

20. Conclusion

So, what are the different types of ischemic heart disease? Stable angina, silent ischaemia, variant angina, microvascular angina, unstable angina, NSTEMI, STEMI, ischaemic cardiomyopathy, arrhythmic sudden death, and MINOCA. Each has a distinct mechanism, investigation and treatment, yet they share the same modifiable risk factors. Timely diagnosis of the correct type and strict preventive therapy transforms outcomes dramatically.

21. References

  1. Thygesen K, et al. Fourth Universal Definition of MI. Circulation 2018; 2023 update.
  2. Vrints C, et al. 2024 ESC Guidelines on Chronic Coronary Syndromes.
  3. Byrne RA, et al. 2023 ESC Guidelines for Acute Coronary Syndromes.
  4. Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline on Coronary Artery Revascularisation.
  5. Agewall S, et al. ESC Working Group Position on MINOCA, 2017; 2024 update.
  6. WHO Cardiovascular Diseases Fact Sheet, 2024.
  7. CDC Heart Disease Facts, 2024.
  8. NHS UK Coronary heart disease overview 2024.

πŸ“ž ENT Consultation & Surgery

Dr. Sagar Rajkuwar (MS-ENT)
Prabha ENT Clinic, Ambad, Nashik
πŸ“± 7387590194 | 9892596635
🌐 www.entspecialistinnashik.com

Medical Disclaimer

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Audiogram results should be interpreted by a qualified audiologist or ENT specialist. If you have sudden hearing loss, severe dizziness, ear discharge, or other concerning symptoms, seek medical evaluation promptly. Always consult a qualified cardiologist for diagnosis and management of any type of ischemic heart disease.